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DERIVATIVES OF ASPIRIN
CROSS-REFERENCE TO RELATED
APPLICATION

Hussain et al copending application, Ser. No. 043,814,

?led concurrently herewith, and.he'reby expressly in
corporated by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to 2-acetoxybenzoic
acid and more particularly, the present invention relates

to therapeutically useful derivatives of Z-acetoxyben
zoic acid, which are substituted l-O-(2'-acetoxy)benz

2

high blood pressure), because it has now been medically
established that the sodium ion contributes to hyperten
sion. Thirdly, the alkaline nature of the product per se
alters the pH of the blood and urine to the alkaline side.
Chronic use of this product could thus initiate alkalosis.
It has also been proposed to avoid the adverse effects
of 2-acetoxybenzoic acid by the use of various esteri?ed

derivatives thereof, wherein transient blocking of the
acidic carboxylic group of aspirin occurs. For instance,
French Patent No. M1453 describes various antipyretic

and analgesic compounds formed by esterifying 2
acetoxybenzoic acid with various sugars. Whether such
derivates are viable substitutes for 2-acetoxybenzoic
5 acid depends not only upon whether these derivatives

oyl-a-D-2-deoxyglucopyranose derivatives.
The novel compounds of this invention exhibit anal

gesic, antipyretic, and antirheumatic therapeutic activ

ity.

have therapeutic value per se, but to a larger extent
upon whether these derivatives have the potential to

revert to 2-acetoxybenzoic acid by hydrolysis in vivo.
In this respect, it is notable that certain derivatives of

The compound 2-acetoxybenzoic acid is commonly

Z-acetoxybenzoic acid tend to hydrolyze so as to form

known as “aspirin” and/or “acetylsalicylic acid”, and is

the corresponding ester of salicylic acid and not aspirin.

one of the most widely used compounds in the treat

The following reaction scheme serves to illustrate the
manner in which derivatives of Z-acetoxybenzoic acid

ment of simple pain and in?ammation. Z-Acetoxyben
zoic acid is widely employed as an analgesic, an antipy
retic, and anti-in?ammatory and an antirheumatic
agent, and it is particularly useful in the relief of fever,

may hydrolyze:

headache, myalgia, arthralgia and other pains associ
ated with integumental structures. Z-Acetoxybenzoic
acid is generally administered for these conditions in the
form of powder, particle, capsule, solution, tablet or

ll

ll

c-o-a

c-o-u

other pharmaceutically acceptable dosage form because
it is advantageous from the standpoint that chronic use
of the compound will not lead to a tolerance or addic

Z-Acetoxybenzoic Acid Ester

tion thereof. Moreover, its toxicity is much lower than
most compounds possessing similar pharmacologic ac 35
tivity. However, Z-acetoxybenzoic acid, as used for
these purposes, is well-known by the practicing skilled
artisan of the medical arts to exhibit certain unwanted
and deliterious side effects. Speci?cally, it induces oc

cult hemorrhaging in the gastrointestinal tract, which

Z-Acetoxybenzoic Acid

(11)

Salicylic Acid Ester

results from contact of the insoluble solid particulate of
It is apparent that only those esteri?ed derivatives of
the compound with the gastrointestinal mucosa. As a
Z-acetoxybenzoic acid which hydrolyze according to
result of this insolubilization, the very acidic particles of
reaction scheme (I), so as to produce aspirin, are viable
2-acetoxybenzoic acid will adhere to the gastrointesti
nal mucosa in the form of crystals and such crystals, 45 substitutes for aspirin. Also, such a substitute must hy
drolyze at a rate sufficient to release aspirin in therapeu
taken together with the acidic environment of the gas

trointestinal lining, will produce microetching thereof,
‘ which in turn, leads to gastrointestinal bleeding.

2. Description of the Prior Art
To date, it is known that gastric bleeding can be
diminished if (1) an aqueous solution of 2-acetoxyben
zoic acid is administered, or (2) a buffered aqueous
solution of 2-acetoxybenzoic acid is administered. How
ever, such solutions leave much to be desired in that

tically effective quantities.
It has recently been discovered that the aspirin deriv

ative,

l-O-(2’-acetoxy)benzoyl-a-D-glucopyranose,

tends to hydrolyze so as to form the corresponding
sugar derivative of salicylic acid, as per reaction scheme
(II) depicted above. Furthermore, to the extent that

hydrolysis to aspirin takes place, such hydrolysis takes

place only at a very slow rate. Cf. the aforenoted Hus
they are commercially and consumerwise unacceptable,
sain et al application, Ser. No. 043,814.
i.e., water and/or buffered solutions are unacceptable as
In summary, the various prior art sugar derivatives of
a suitable pharmaceutical dosage form.
2-acetoxybenzoic acid present a non-irritating neutral
' One product on the market, commercially known as
molecule to the gastrointestinal lining when adminis
“Alka-Seltzer ®” is basically an alkaline effervescent
Z-acetoxybenzoic acid formulation, which does exhibit 60 tered for therapeutic purposes. However, the group
which blocks the carboxylic acid function of Z-acetox
satisfactory water solubility and dissolution, insofar as
ybenzoic acid tends to be bound thereto very tightly.
2-acetoxybenzoic acid is concerned. However, at least
Such prior art derivatives, therefore, do not release
three disadvantages are associated with this product.
aspirin in vivo in therapeutically suf?cient quantities.
Firstly, the product is contained in a tablet form and
must initially be dissolved in water prior to consump 65 Thus, a need exists for a 2-acetoxybenzoic acid deriva

tion. Secondly, because the product contains a high
amount of sodium ion, it is unacceptable for administra
tion to hypertensive patients (those who suffer from

tive, wherein transient blocking of the carboxylic func
tion occurs, yet wherein the blocking group is not so

tenaciously bound thereto.
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4
-continued

SUMMARY OF THE INVENTION
Accordingly, it is onelobject of the present invention

R

to provide a derivative of Z-acetoxybenzoic acid which
5 (1)
does not tend to cause local irritation of the gastrointes
tinal tract, yet which is capable of hydrolyzing at a rate
sufficient to release 2-acetoxybenzoic acid in vivo in
therapeutically sufficient quantities.

}

+

CHZCI

UB2

KOH

HEAT

B20

9 CHFO

B2 = —CH2¢

O

CHZOBZ

-

(II)

It is another object of the present invention to pro
vide a derivative of 2-acetoxybenzoic‘acid which will
permit a therapeutically effective compound to be ab
sorbed through the gastrointestinal lining, in a manner

R
0132
GLACIAL ACETIC ACID

(u)

2N H2504 HEAT

B20

9H0

such that insoluble, acidic particles of Z-acetoxybenzoic
acid are not contacted therewith, thus eliminating gas
trointestinal bleeding.

o

CHZOBZ

I

(HA)

Finally, it is yet another object of ‘the present inven
tion, to provide a derivative of 2-acetoxybenzoic acid,

0

which can be formulated in a suitable oral pharmaceuti

c-c1

ll
(HA) +

cally acceptable dosage form forpadministration as an
analgesic, an antipyretic, an anti-in?ammatory and an
antirheumatic agent to warm-blooded animals.

PYRIDINE ;
o-c-cu;

ll

These and other objects of the instant invention will
25
become more readily apparent from a reading of the

0

accompanying disclosure and appended claims thereto.

c-—o—-nA

ll

The foregoing objects are attained with the use of

novel acylal derivatives of 2-acetoxybenzoic acid, the
structure of which may be represented by the following

O-—?—Cl-I3
0

(111)

formula I

R

H

OH

C_O

35

H0

H2 - Pd/C

(In) +

O

O-?-CH; CHZOH
'

0

PRODUCT

The above‘ method is basically a modi?cation of the

wherein R represents amino, lower monoalkylamino,
lower dialkylamino, 7 lower alkyl, lower cycloalkyl,

lower hydroxy-substituted alkyl, lower alkoxy or piper

45

idino.

scheme will be apparent to those skilled in the art. For

DETAILED DESCRIPTION OF THE
INVENTION

If the substituent R within the compounds of formula
I includes lower alkyl groups, these alkyl group contain
e.g., 1-4 carbon atoms. If the lower alkyl is unsubsti
tuted, methyl is preferred; in the case of hydroxy‘substi

tuted alkyl, 2-hydroxy-alkyl is preferred. Lower cyclo

50

55

the benzyl protecting groups. After coupling, benzyl
and p-methoxybenzyl protecting groups can be conve

Raney nickel, and palladium (optionally on a support), a
60

particularly preferred catalyst being palladium-on-car
bon. When protecting groups which are normally not

R

OH

on

HO $?-cm-o

HO

sensitive to catalytic hydrogenolysis, e.g., tert-butyl
radicals, are employed, removal may be effected by use
of an acid such as trifluoroacetic acid. If R is hydroxyal

kyl group, the latter, of course, will react towards any

o

cnzon

coupling of the substituted a-D-Z-deoxyglucopyranose
and the 2-acetoxybenzoic acid portions of the molecule.

niently removed by catalytic hydrogenolysis. Suitable
catalysts may include rhodium, platinum, ruthenium,

cording to the following scheme:

0

example, protecting groups other than benzyl can be
employed, so long as they can be readily removed after

Thus, p-methoxybenzyl or tert-butyl radicals could be
introduced into the glucopyranose derivative instead of

alkyl groups R may comprise e.g., 3-5 carbon atoms.
The compounds of formula I can be synthesized ac

CH3OH + HO

method reported by Glaudemans and Fletcher in Meth
ods 0f Carbonhydrate Chemistry, Volume VI, R. I...
Whistler and J. N. Bemiller, Eds., Academic Press,
New York, NY. (1972), pp. 373-376.
Numerous modi?cations in the depicted reaction

cnzou
(I)

protective group in the same manner as the hydroxy~

methyl group in 5-position of the glucopyranose nu
cleus.
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Variations in thecoupling
5 reaction .would;also~ be
possible. For example, the acid chloride starting mate
rial could be reacted with the protectedglucopyranose

in the presence of suitable bases other than pyridine,
e.g., other tertiary aliphatic oraromatic amines such as

N~methylmorpholine, triethylamine, and picoline, con;
veniently in -a non-protic solvent.-,Alternatively,. the
protected glucopyranose could be. reacted with 2

acetoxybenzoic acid (rather than with?the acid chlo
ride), in which case the reaction would be conductedin
the presence of a suitable dehydrating agent, for exam

6
.‘Although the present invention has been adequately

described in the foregoing speci?cation, it is, apparent
that various changes and/or modifications can belmade

thereto by the skilled artisan without departing from the
spirit and scope thereof. Such changes and/or modi?ca
tions are properly, equitably and intended to be within
the full range of equivalence of the following claims:
What. is claimed is:

1.

An .

'

l-O-(2’acetoxy)benzyl-d-D-2-deoxy

glucopyranose derivative having the formula

ple, an aromatic or aliphatic carbodiimide. '

R

The rate of generation of aspirin via hydrolysis of its
derivatives of the present invention can be determined
spectrophotometrically. Determination of rate of gener

ation of aspirin from its pro-drugs according to the
present invention were made using solutions ranging
from pH 1.2 to pH 9.
The generation of aspirin from the derivatives was
found to be largely independent of the pH of the solu 20
tions. The half-life for the hydrolysis at pH 3 and pH 8
at 37° C. was found to be in the range of several min
utes, e.g., between 5 and 10 minutes.
Thus, the transient blocking of the acidic carboxylic I

group of aspirin by formation of an acylal-linked deriva 25
tive results in a compound which regenerates aspirin at
an acceptablerate. Such a compound reduces the gas

trointestinal liability of aspirin by presenting a neutral
molecule to the gastric membrane.

, I

The compounds of this invention are conveniently
administered in oral dosage form, such as by tablet or
capsule, by combining the same in a therapeutic amount
(e. g., dosage regimen for aspirin on an equivalent

if
C_O

0H
HO
0

CHZOI-I

wherein R represents amino, lower monoalkylamino,
lower dialkylamino, piperidino, lower alkyl, lower cy
cloalkyl, lower alkoxy or hydroxy-substituted lower

alkyl.
2. A method for inducing an analgesic, antipyretic,
antirheumatic or anti-in?ammatory response in a warm

blooded animal which comprises orally administering
thereto an effective amount of l-O-(2’-acetoxy)benzoyl
a-D-Z-deoxyglucopyranose derivative as de?ned in
claim 1;

weight basis) with any oral pharmaceutically accept

3. A pharmaceutical composition of matter adapted
for oral administration comprising an effective analge
sic, antipyretic, antirheumatic or anti-in?ammatory

cal grade), dicalcium phosphate, calcium sulfate, kaolin,

glucopyranose derivative as de?ned in claim 1 and a

mannitol, and powdered sugar. In addition, when re
quired, suitable binders, - lubricants, disintegrating
agents, and coloring agents can also be added. Typical
binders include starch, gelatin, sugars, such as sucrose,
molasses, and lactrose, natural and synthetic gums such

4. The compound as de?ned by claim 1, wherein R is
amino.
5. The compound as de?ned in claim 1, wherein R is

able inert carrier, such as lactose, starch (pharmaceuti 35 amount of an 1-O-(2'-acetoxy)benzoyl-a-D-2-deoxy

as acacia, sodium alginate, extract of Irish moss, carbox

ymethylcellulose, methylcellulose, and polyvinylpyr

pharmaceutically acceptable inert carrier.

lower alkyl.
6. The compound as de?ned in claim 1, wherein R is

lower monoalkylamino.

7. The compound as de?ned in claim 1, wherein R is
rolidone, polyethyleneglycol, ethylcellulose and waxes.
Typical lubricants for use in these dosage forms can 45 lower dialkylamino.
8. The compound as de?ned in claim 1, wherein R is
include, without limitation, sodium benzoate, sodium

acetate, sodium chloride, leucine and polyethyleneg
lycol. Suitable disintegrators can include, without limi
tation, starch, methylcellulose, agar, bentonite, cellu
lose and wood products, alginic acid, guar gum, citrus

pulp, carbonmethylcellulose and sodium lauryl sulfate.
If desired, a conveniently pharmaceutically acceptable
dye can be incorporated into the dosage unit form, i.e.,
any of the standard FD&C dyes.

piperidino.

9. The compound as de?ned in claim 1, wherein R is

lower cycloalkyl.
10. The compound as de?ned in claim 1, wherein R is

lower alkoxy.
11. The compound as de?ned in claim 1, wherein R is

hydroxy-lower alkyl.

12. The compound as de?ned by claim 5, wherein R
Any skilled artisan can prepare these oral dosage 55 is methyl.
13. The compound as de?ned by claim 11, wherein R
forms by simply referring to the oral dosage form pre
is 2-hydroxyalky1.
paratory procedure outlined in “REMINGTON’S
14. A compound having the structural formula:
PHARMACEUTICAL SCIENCES,” Fourteenth

Edition (1970), pp. 1659-1698, inclusive.
The dose administered, whether a single dose or a 60

daily dose will, of course, vary with the needs of the

individual being treated. However, the dosage adminis
tered is not subject to de?nite bounds, but it will usually
be an effective therapeutic amount, or the equivalent on

a molar basis of the pharmacologically-active form 65
produced upon the metabolic release of the active drug
(Z-acetoxybcnzoic acid) to achieve its desired pharma
cological or physiological effect.

7
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anti-inflammatory response.
19. The composition as de?ned by claim 3, compris
ing an analgesic amount of said derivative.

alkyl, and R‘ is selected from the group consisting of

20. The composition as de?ned by claim 3, compris

benzyl, p-methoxybenzyl and tert-butyl.

ing an antipyretic amount of said derivative.
21. The composition as de?ned by claim 3, compris

15. The method as de?ned by claim 2, for inducing an
analgesic response.

ing an antirheumatic amount of said derivative.

16. The method as de?ned by claim 2, for inducing an

antipyretic response.
17. The method as de?ned by chim 2, for inducing an
antirheumatic response.

8

18. The method as de?ned by claim 2, for inducing an

wherein R represents amino, lower monoalkylamino,
lower dialkylamino, piperidino, lower alkyl, lower cy
cloalkyl, lower alkoxy or hydroxyvsubstituted lower

0

22. The composition as de?ned by claim 3, compris
ing an anti-inflammatory amount of said derivative.
*
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